Xeris' G-Pen increases plasma glucose in Phase III pediatric hypoglycemia

Xeris Pharmaceuticals Inc. (NASDAQ:XERS) said its G-Pen glucagon injection rescue pen significantly increased mean plasma glucose levels within 30 minutes by at least 25 mg/dL in all patients in a Phase III trial to treat hypoglycemia in pediatric Type I diabetics.

The open-label, U.S. trial enrolled 31 patients to receive 0.5 or 1 mg glucagon in the G-Pen...